Takeda Announces U.S. FDA Breakthrough Therapy Designation For Mobocertinib(TAK-788) For The Treatment Of NSCLC Patients With E

Takeda Announces U.S. FDA Breakthrough Therapy Designation For Mobocertinib(TAK-788) For The Treatment Of NSCLC Patients With EGFR Exon 20 Insertion Mutations

April 30, 2020

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation ...

Takeda Comments On Ongoing Phase 1 Review By The European Commission Of The Proposed Acquisition Of Shire PLC

by admin

October 28, 2018

598

50

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO ...

Takeda To Highlight Data In Hodgkin Lymphoma During The 11th International Symposium On Hodgkin Lymphoma

by admin

October 28, 2018

33

65

– Six Abstracts to be Presented to Highlight the Potential Impact of ADCETRIS® (brentuximab vedotin) for the Treatment of Hodgkin Lymphoma ...

Takeda Establishes Record Date For Extraordinary General Meeting Of Shareholders

by admin

October 1, 2018

10

58

Company Announces Record Date and Highlights Significant Progress To-Date OSAKA, Japan--(BUSINESS WIRE/AETOSWire)-- Further to the announcement of the recommended acquisition ...

Tag: Takeda